Page last updated: 2024-12-06
amogastrin
Description
amogastrin: used in conjunction with pertechnetate for gastric scintigraphy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 71884 |
CHEMBL ID | 3187384 |
CHEBI ID | 31207 |
SCHEMBL ID | 2733789 |
MeSH ID | M0109135 |
Synonyms (37)
Synonym |
alaninamide, n-carboxy-l-tryptophyl-l-methionyl-l-aspartylphenyl-, n-tert-pentyl ester, l- |
amogastrina [inn-spanish] |
amogastrin |
n-((1,1-dimethylpropoxy)carbonyl)-l-tryptophyl-l-methionyl-l-alpha-aspartyl-l-phenylalaninamide |
n-carboxy-l-tryptophyl-l-methionyl-l-alpha-aspartyl-3-phenyl-l-alaninamide n-tert-pentyl ester |
l-phenylalaninamide, n-((1,1-dimethylpropoxy)carbonyl)-l-tryptophyl-l-methionyl-l-alpha-aspartyl- |
aoc-tetragastrin |
amogastrine [inn-french] |
tert-amyloxycarbonyltetragastrin |
amogastrinum [inn-latin] |
amogastrin [inn:jan] |
tert-pentyl n-carboxylato-tryptophyl-methionyl-alpha-aspartyl-phenylalanylamid |
16870-37-4 |
D01237 |
amogastrin (jan/inn) |
(3s)-4-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2s)-2-[[(2s)-3-(1h-indol-3-yl)-2-(2-methylbutan-2-yloxycarbonylamino)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid |
NCGC00182027-01 |
dtxcid8028503 |
cas-16870-37-4 |
tox21_112905 |
dtxsid8048577 , |
amogastrinum |
amogastrina |
amogastrine |
8t3q0x4g5g , |
unii-8t3q0x4g5g |
(3s)-4-(((1s)-2-amino-1-benzyl-2-oxo-ethyl)amino)-3-((2s)-2-(((2s)-2-(1,1-dimethylpropoxycarbonylamino)-3-(1h-indol-3-yl)propanoyl)amino)-4-methylsulfanyl-butanoyl)amino)-4-oxo-butanoic acid |
n-((1,1-dimethylpropoxy)carbonyl)-l-tryptophyl-l-methionyl-l-.alpha.-aspartyl-l-phenylalaninamide |
amogastrin [who-dd] |
l-phenylalaninamide, n-((1,1-dimethylpropoxy)carbonyl)-l-tryptophyl-l-methionyl-l-.alpha.-aspartyl |
amogastrin [inn] |
amogastrin [jan] |
SCHEMBL2733789 |
CHEMBL3187384 |
CHEBI:31207 |
Q27270979 |
AKOS040750481 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Drug Classes (1)
Class | Description |
oligopeptide | A peptide containing a relatively small number of amino acids. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (2)
Potency Measurements
Ceullar Components (1)
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (16.67%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |